Progress Toward an All Oral Treatment for Newly Diagnosed Older Adults with AML with Gabriel Mannis, MD
Spotify%20--%3e%3csvg%20version='1.1'%20id='Livello_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20width='300px'%20height='300px'%20viewBox='0%200%20300%20300'%20enable-background='new%200%200%20300%20300'%20xml:space='preserve'%3e%3cg%20id='XMLID_632_'%3e%3clinearGradient%20id='XMLID_2_'%20gradientUnits='userSpaceOnUse'%20x1='150'%20y1='0'%20x2='150'%20y2='300'%3e%3cstop%20offset='0'%20style='stop-color:%23F452FF'/%3e%3cstop%20offset='1'%20style='stop-color:%23832BC1'/%3e%3c/linearGradient%3e%3cpath%20id='XMLID_662_'%20fill-rule='evenodd'%20clip-rule='evenodd'%20fill='url(%23XMLID_2_)'%20d='M294.1,260c-2.9,7.4-9.6,17.8-19.2,25.2%20c-5.5,4.2-12.1,8.3-21.1,11c-9.6,2.9-21.5,3.8-36.3,3.8h-135c-14.8,0-26.6-1-36.3-3.8c-9-2.7-15.6-6.7-21.1-11%20c-9.5-7.3-16.3-17.8-19.2-25.2C0.1,245.1,0,228.2,0,217.5l0,0v-135l0,0C0,71.8,0.1,54.9,5.9,40c2.9-7.4,9.6-17.8,19.2-25.2%20c5.5-4.2,12.1-8.3,21.1-11C55.9,1,67.7,0,82.5,0l0,0h135l0,0c14.8,0,26.6,1,36.3,3.8c9,2.7,15.6,6.7,21.1,11%20c9.5,7.3,16.3,17.8,19.2,25.2c5.9,14.9,5.9,31.9,5.9,42.5v135C300,228.2,299.9,245.1,294.1,260z'/%3e%3cg%3e%3cpath%20id='XMLID_657_'%20fill='%23FFFFFF'%20d='M175.7,181.1c-0.4-3.6-1.6-6.2-4-8.6c-4.5-4.7-12.4-7.8-21.7-7.8c-9.3,0-17.2,3-21.7,7.8%20c-2.3,2.5-3.6,5-4,8.6c-0.8,7-0.3,13,0.5,22.7c0.8,9.2,2.3,21.5,4.2,33.9c1.4,8.9,2.5,13.7,3.5,17.1c1.7,5.6,7.8,10.4,17.5,10.4%20c9.7,0,15.9-4.9,17.5-10.4c1-3.4,2.1-8.2,3.5-17.1c1.9-12.5,3.4-24.7,4.2-33.9C176.1,194.1,176.5,188.1,175.7,181.1z'/%3e%3cpath%20id='XMLID_655_'%20fill='%23FFFFFF'%20d='M174.6,130.1c0,13.6-11,24.6-24.6,24.6s-24.6-11-24.6-24.6c0-13.6,11-24.6,24.6-24.6%20S174.6,116.6,174.6,130.1z'/%3e%3cpath%20id='XMLID_653_'%20fill='%23FFFFFF'%20d='M149.7,33.2C92.3,33.4,45.3,80,44.5,137.4c-0.6,46.5,29.1,86.3,70.6,100.9%20c1,0.4,2-0.5,1.9-1.5c-0.5-3.6-1.1-7.2-1.5-10.8c-0.2-1.3-1-2.3-2.1-2.9c-32.8-14.3-55.7-47.2-55.3-85.3%20c0.5-50,41.3-90.7,91.2-91.1c51.1-0.4,92.8,41,92.8,92c0,37.7-22.8,70.1-55.3,84.4c-1.2,0.5-2,1.6-2.1,2.9%20c-0.5,3.6-1,7.2-1.5,10.8c-0.2,1.1,0.9,1.9,1.9,1.5c41.1-14.4,70.6-53.6,70.6-99.6C255.5,80.5,208,33.1,149.7,33.2z'/%3e%3cpath%20id='XMLID_651_'%20fill='%23FFFFFF'%20d='M147.3,68.2c-37.4,1.4-67.4,32.3-67.9,69.7c-0.3,24.6,12,46.4,30.9,59.3%20c0.9,0.6,2.2-0.1,2.2-1.2c-0.3-4.3-0.3-8.1-0.1-12.1c0.1-1.3-0.4-2.5-1.4-3.4c-11.5-10.8-18.5-26.2-18.1-43.2%20c0.8-30,24.9-54.4,54.9-55.6c32.6-1.3,59.4,24.9,59.4,57.1c0,16.4-7,31.2-18.1,41.7c-0.9,0.9-1.4,2.1-1.4,3.4%20c0.2,3.9,0.1,7.7-0.1,12c-0.1,1.1,1.2,1.9,2.2,1.2c18.6-12.7,30.9-34.2,30.9-58.4C220.8,98.9,187.5,66.6,147.3,68.2z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Apple PodcastsIn this HealthTree Radio for AML show, Dr. Gabriel Mannis talks about treatment options for older adults with AML. He reviews his open clinical trial looking at what could be the first all-oral treatment for newly diagnosed older patients. The combination of venetoclax and decitabine with cedazuridine (ASTX727 or Inqovi) would provide older adults with AML and those who cannot tolerate standard intensive chemotherapy a much-needed alternative treatment option.
To listen to the recording or read the transcript of this past radio show,
Gabriel Mannis, MD
Stanford Cancer Institute
Interview Date: September 13th, 2021
Dr. Gabriel Mannis of the Stanford Cancer Institute is studying what could become the first all oral therapy for older adults with newly diagnosed AML. The combination of venetoclax and decitabine with cedazuridine (a combination medication called ASTX727 or Inqovi) would provide older adults and those who cannot tolerate standard intensive chemotherapy a much needed alternative treatment option. Dr. Mannis shares details about how hypomethylating agents combined with venetoclax is an effective combination for older adults with AML and how oral therapies can give patients the freedom to live their lives without being confined to a hospital room. Medication options for older adults with AML are significantly advancing and becoming more effective. This exciting trial aims to add another treatment option to a patient's arsenal.
To learn more about the trial being discussed in today's episode,
Thanks to our episode sponsor
%20-%20smaller%20jpg_5093a115-769d-4cb8-99c4-e07244874f4d.jpg?alt=media){kind=logo}
Gabriel Mannis, MD
Katie Braswell